humanin and Medulloblastoma

humanin has been researched along with Medulloblastoma* in 3 studies

Other Studies

3 other study(ies) available for humanin and Medulloblastoma

ArticleYear
The humanin analogue (HNG) prevents temozolomide-induced male germ cell apoptosis and other adverse effects in severe combined immuno-deficiency (SCID) mice bearing human medulloblastoma.
    Experimental and molecular pathology, 2019, Volume: 109

    Subfertility is a major concern of long-term cancer survivors at the reproductive age. We have previously demonstrated that a potent humanin analogue, HNG, protected chemotherapy-induced apoptosis in germ cells but not cancer cells in a metastatic melanoma allograft model. In this study, we utilized severe combined immuno-deficiency (SCID) mice bearing human medulloblastoma to study the effect of HNG in Temozolomide (TMZ) induced male germ cell apoptosis and white blood cell (WBC) suppression. Human medulloblastoma DAOY cells were injected subcutaneously into the right flank of male SCID mice. Three weeks later, groups of tumor-bearing mice received one of the following treatments: vehicle, HNG, TMZ, or TMZ + HNG. 24 h after last injection, the tumors weights, complete blood counts, liver and spleen weights, male germ cell apoptosis was assessed. HNG did not affect TMZ's significant anti-tumor action. HNG significantly prevented TMZ-induced germ cell apoptosis and attenuated the suppressed total WBC and granulocyte counts in SCID mice with or without TMZ treatment. HNG also attenuated TMZ-induced body weight loss and decrease of spleen and liver weights. In conclusion, HNG ameliorated TMZ-induced germ cell apoptosis; WBC and granulocytes loss; and decreased body/organ weights without compromising the TMZ's anti-cancer action on medulloblastoma xenografts in SCID mice.

    Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cerebellar Neoplasms; Humans; Intracellular Signaling Peptides and Proteins; Liver; Male; Medulloblastoma; Mice, SCID; Organ Size; Spermatozoa; Spleen; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays

2019
New role for the mitochondrial peptide humanin: protective agent against chemotherapy-induced side effects.
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Development; Boronic Acids; Bortezomib; Humans; Intracellular Signaling Peptides and Proteins; Male; Medulloblastoma; Neuroblastoma; Proteasome Inhibitors; Pyrazines

2014
Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatment.
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:3

    Bortezomib is a proteasome inhibitor currently studied in clinical trials of childhood cancers. So far, no side effects on bone growth have been reported in treated children. However, bortezomib was recently found to induce apoptosis in growth plate chondrocytes and impair linear bone growth in treated mice. We hypothesize that [Gly(14)]-humanin (HNG), a 24-amino acid synthetic antiapoptotic peptide, can prevent bortezomib-induced bone growth impairment.. Mice with human neuroblastoma or medulloblastoma tumor xenografts (9-13 animals/group) received one 2-week cycle (2 injections/week) of bortezomib (0.8 mg/kg or 1.0mg/kg), or HNG (1 µg/mouse), or the combination of HNG/bortezomib, or vehicle. Cultures of human growth plate cartilage, chondrogenic- and cancer cell lines, and immunohistochemistry for detection of proapoptotic proteins were also used. Statistical significance was evaluated by two-sided Mann-Whitney U test or by parametric or nonparametric analysis of variance.. Bortezomib efficiently blocked the proteasome and induced pronounced impairment of linear bone growth from day 0 to day 13 (0.09 mm/day, 95% confidence interval [CI] = 0.07 to 0.11 mm/day; vs 0.19 mm/day, 95% CI = 0.15 to 0.23 mm/day in vehicle; P < .001), an effect significantly prevented by the addition of HNG (0.15 mm growth/day, 95% CI = 0.14 to 0.16 mm/day; P < .001 vs bortezomib only; P = 0.03 vs vehicle). Bortezomib was highly toxic when added to cultures of human growth plate cartilage, with markedly increased apoptosis compared with control (P < .001). However, when combining with HNG, bortezomib-induced apoptosis was entirely prevented, as was Bax and PARP activation. Bortezomib delayed tumor growth, and HNG did not interfere with the anticancer effect when studied in human tumor xenografts or cell lines.. HNG prevents bortezomib-induced bone growth impairment without interfering with bortezomib's desired anticancer effects.

    Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Development; Boronic Acids; Bortezomib; Cell Line, Tumor; Chondrocytes; Dose-Response Relationship, Drug; Drug Administration Schedule; Femur; Growth Plate; Heterografts; Humans; Intracellular Signaling Peptides and Proteins; Male; Medulloblastoma; Metatarsal Bones; Mice; Mice, Nude; Neuroblastoma; Proteasome Inhibitors; Pyrazines; Time Factors

2014